Advertisement

Topics

Better Results in NSCLC with Higher Dose of ALK Inhibitor (CME/CE)

13:45 EDT 7 Aug 2017 | MedPageToday

(MedPage Today) -- Response, PFS improved with 180 mg of brigatinib

Original Article: Better Results in NSCLC with Higher Dose of ALK Inhibitor (CME/CE)

NEXT ARTICLE

More From BioPortfolio on "Better Results in NSCLC with Higher Dose of ALK Inhibitor (CME/CE)"

Quick Search
Advertisement